Sign Up

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

WASHINGTON, July 16, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the "Company" or "60 Degrees") (NASDAQ:SXTP, SXTPW)), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced public offering of 2,631,578 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series A-1 warrants to purchase up to 2,631,578 shares of common stock and short-term Series A-2 warrants to purchase up to 2,631,578 shares of common stock, at a combined offering price of $1.90 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants.

The Series A-1 warrants have an exercise price of $1.90 per share, are exercisable upon issuance and expire five years thereafter. The short-term Series A-2 warrants have an exercise price of $1.90 per share, are exercisable upon issuance and expire 18 months thereafter.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Total gross proceeds to the Company from the offering were $5 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the short-term Series A-2 warrants, if fully exercised on a cash basis, will be approximately $5 million. No assurance can be given that any of the short-term Series A-2 warrants will be exercised. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-288550) originally filed with the Securities and Exchange Commission ("SEC") on July 7, 2025, and declared effective on July 15, 2025. The offering was made only by means of a prospectus, which forms a part of the effective registration statement. A final prospectus relating to the offering has been filed with the SEC and is available for free on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New ...